The infant formula market has more than doubled over the past decade. But not all companies have managed to keep up, thus making it a lucrative market for the few that have. Infant formula companies, like Bubs Australia (ASX: BUB), saw it as an opportunity to expand into global markets, even becoming one of the
Read More
After a successful entry into the USA during their recent dairy crisis, infant nutrition and dairy specialist Bubs Australia (ASX: BUB) has lodged a letter of intent to continue selling six Bubs Infant Formula products in the country till October 2025 and beyond. The Australian Company is one of only eight infant formula manufacturers globally
Read More
It’s hard to believe that in 2022 food security in America would be an issue, but for thousands of parents, feeding their babies is a daily struggle. The US baby formula crisis was the perfect storm of a monopolised market, a serious food recall and a sloppy government response. The story in a nutshell? Major
Read More
It’s the most talked about stock in the retail investor community right now, and having climbed 61.84% in the past month it may be for a while yet. I’m talking about Bubs (ASX: BUB), the company coming to the rescue of US parents who are the unfortunate victims of the US formula crisis. The serious
Read More
Shareholders of Bubs Australia (ASX: BUB) reveled in every small cap investors’ dream over the weekend – a direct shoutout from the President of the United States. And this morning the President issued a follow-up that will renew shareholders’ excitement – it might not quite get the attention of an incendiary ex President Trump tweet,
Read More
As is becoming the case across the consumer products industry, millenials are wielding unprecedented power through irrational spending and influencer marketing. So it comes as no surprise that infant formula manufacturer Bubs (ASX: BUB) has launched a new natural A2 beta-casein protein product to quench their demand. The new product is an extension of Bubs’
Read More